A landmark moment in IPF care
Introducing JASCAYD®–the first new IPF treatment in 10 years, transforming care and expanding what’s possible for your patients1,2
Novel mechanism of action
JASCAYD® is a preferential PDE4B inhibitor with antifibrotic, immunomodulatory, and vascular effects3,4
Proven efficacy
JASCAYD® demonstrated a statistically significant reduction in FVC decline5
Well tolerated
JASCAYD® has a favorable tolerability and safety profile6
IPF, idiopathic pulmonary fibrosis.
References
-
Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Published September 16, 2024. Accessed February 20, 2026. https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/nerandomilast-primary-endpoint-phase-3-fibroneer-ild-pulmonary-fibrosis
-
OFEV® Summary of Product Characteristics UAE; June 2025.
-
Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.
-
Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700-712.
-
Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202.
-
Oldham JM, Azuma A, Kreuter M, et al. Effect of nerandomilast on clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF): data from final database lock of the FIBRONEER-IPF trial. Presented at: European Respiratory Society (ERS) International Congress; September 2025. Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Oldham1
MLR ID: PC-AE-102892
Expiry Date: 10/05/2028